In 1997, Vogelzang et al. reported that 61 % of patients with cancer indicated fatigue impacted daily life more than pain, and only 37 % of oncologists shared this perception. We provide an update to this study, which can help prioritize symptom assessment and management in the clinic. Study aims were to determine and compare perceptions of patients with cancer and health care providers (HCPs) of the impact of fatigue and pain.
A random sample of patients with cancer was recruited in the USA by Harris Poll Online and Schlesinger Associates. Oncology HCPs were recruited by Food and Drug Research, Inc. and Toluna, Inc.
From June to November 2012, 550 of 1122 eligible patients (49 %), 400 of 533 eligible oncologists (75 %), and 400 of 617 eligible oncology nurses (65 %) completed a survey. Of patients, 58 % reported that fatigue affected their daily lives more than pain while undergoing treatment with chemotherapy versus 29 % of oncologists and 25 % of oncology nurses that had this perception. Ninety-eight percent of patients reported experiencing fatigue, whereas 72 % of oncologists and 84 % of oncology nurses thought this was the case. Eighty-six percent of patients reported pain while undergoing treatment with chemotherapy, whereas 36 % of oncologists and 51 % of oncology nurses believed this occurred. Nausea and vomiting felt by HCPs were the most concerning symptoms for patients (88 %).
This study shows the importance of assessing symptoms by direct patient report during chemotherapy treatment. HCPs continue to underestimate the prevalence and importance of fatigue and pain for patients with cancer, a finding that may alter the management of treatment-related symptoms and may influence the development of patient symptom management plans.
ESM 1 (DOC 173 kb)520_2016_3275_MOESM1_ESM.doc
Richardson A (1995) Fatigue in cancer patients: a review of the literature. Eur J Cancer Care 4(1):20–32 CrossRef
Cella D, Davis K, Breitbart W et al (2001) Cancer-related fatigue: prevalence of proposed diagnostic criteria in a United States sample of cancer survivors. J Clin Oncol 19(14):3385–3391 PubMed
Demetri GD, Kris M, Wade J et al (1998) Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 16(10):3412–3425 PubMed
Littlewood TJ, Bajetta E, Nortier JW et al (2001) Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 19(11):2865–2874 PubMed
Vogelzang NJ, Breitbart W, Cella D et al (1997) Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The fatigue coalition. Semin Hematol 34(3 Suppl 2):4–12 PubMed
Basch E (2014) The rationale for collecting patient-reported symptoms during routine chemotherapy. Am Soc Clin Oncol Educ Book 2014:161–165 CrossRef
Guidance for industry: patient reported outcome measures: use in medical product development to support labelling claims. Silver Spring, MD: Food and Drug Administration, 2009. Available from: http://www.fda.gov/downloads/Drugs/Guidances/UCM193282.pdf. Accessed 13 Jan 2016.
Reflection paper on the use of patient reported outcomes (PRO) measures in oncology studies. London, United Kingdom: European Medicines Agency, 2014. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/06/WC500168852.pdf. Accessed 13 Jan 2016.
Cramp F, Daniel J (2008) Exercise for the management of cancer-related fatigue in adults. Cochrane Database Syst Rev 2:CD006145 PubMed
Paoli CJ, Bach BA, Quach D et al (2014) Performance status of real-world oncology patients before and after first course of chemotherapy. J Community Support Oncol 12:163–170 CrossRef
- Patient and health care provider perceptions of cancer-related fatigue and pain
Loretta A. Williams
- Springer Berlin Heidelberg
Neu im Fachgebiet Onkologie
Mail Icon II